From Earlier: Inovio Receives U.S. Patent for SynCon H1N1 Influenza Universal Vaccine
Inovio Pharmaceuticals, Inc. (NYSE: INO) announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering Inovio's SynCon® universal vaccine related to H1N1 influenza. The patent granted to the Trustees of The University of Pennsylvania has been licensed exclusively to Inovio under its existing license agreement with the university.
The patent includes claims that cover the synthetic consensus H1 antigen and DNA constructs and vaccines that include this antigen, including universal influenza vaccine INO-3510. This patent also covers methods of treating a patient using the SynCon® universal influenza vaccine.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.